

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

(1) CHANGE OF CHAIRMAN OF THE BOARD;
(2) CHANGE OF DIRECTORS; AND
(3) CHANGE OF COMPOSITION OF BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Health Group Limited (the “**Company**”) hereby announces the change of Directors as follows:

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHAIRMAN OF THE BOARD

Mr. Cao Xu (“**Mr. Cao**”) has been appointed as an executive Director, the chairman of the Board and the chairman of the Nomination Committee with effect from 31 October 2025.

The biographical details of Mr. Cao are as follows:

Mr. Cao, aged 43, has approximately 14 years of experience in investments and approximately four years of experience in the pharmaceutical industry. From July 2007 to April 2011, he held the position of lead healthcare engineer at the pharmaceutical engineering department at Bayer Technology and Engineering (Shanghai) Co., Ltd. (拜耳技術工程(上海)有限公司), where he was mainly responsible for process design and compliance certification of pharmaceutical projects. From May 2011 to June 2016, Mr. Cao served as a senior investment manager at Tianjin Binhai New Area Guiding Fund and Venture Capital Co., Ltd (天津濱海新區創業風險投資引導基金有限公司), where he was responsible for overseeing venture capital and fund-of-funds. From July 2016 to December 2020, he became a deputy general manager at CCBI Wealth Management (Beijing) Co., Ltd. (建銀國際產業基金管理(北京)有限公司). Currently, he is a partner at CDH Investment Co., Ltd. (上海鼎暉百孚投資管理有限公司) since December 2020. Mr. Cao currently also serves as a non-executive director of Cloudbreak Pharma Inc. (a company listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), stock code: 2592).

Mr. Cao obtained a master's degree in science in biochemical engineering from Zhejiang University, China in June 2007, and a bachelor's degree in biological engineering from Zhejiang University, China in June 2005. Mr. Cao also holds a fund practitioner qualification (基金從業資格) granted by the Asset Management Association of China (中國證券投資基金業協會) in May 2017.

Mr. Cao has entered into a service contract with the Company commencing from 31 October 2025 for a term of two years unless terminated by either party giving not less than one month's notice in writing to the other party. He is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. Mr. Cao is entitled to a remuneration fee of HK\$60,000 per month which is determined with reference to his duties, responsibilities and experience, and to prevailing market conditions, and is subject to annual review by the Remuneration Committee of the Company.

Save as disclosed above, Mr. Cao (i) has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other positions in the Company or its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") of the Company; and (iv) does not have or is not deemed to have any interests or short positions in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information relating to Mr. Cao that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warm welcome to Mr. Cao for joining the Board.

APPOINTMENT OF EXECUTIVE DIRECTOR

Ms. Ying Rensi ("**Ms. Ying**") has been appointed as an executive Director with effect from 31 October 2025.

The biographical details of Ms. Ying are as follows:

Ms. Ying, aged 30, is a general manager and executive director of 脈福(深圳)醫療生物科技股份有限公司 (“**Maifu**”) since February 2024, and the chief executive officer of Mineup LLC (“**Mineup**”) since 2017. Maifu is a PRC company and principally engaged in the sale and distribution of medical equipment business. Mineup is a multimedia design creative agency located in the United States. Ms. Ying is mainly responsible for overseeing Mineup’s overall strategic direction, managing key partnerships, supervising executive-level operations, and leading cross-functional teams in the development of innovative creative and digital media solutions. Ms. Ying holds a master’s degree in Architecture from Columbia University.

Ms. Ying has entered into a service contract with the Company commencing from 31 October 2025 for a term of two years unless terminated by either party giving not less than one month’s notice in writing to the other party. She is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. Ms. Ying is entitled to a remuneration fee of HK\$60,000 per month which is determined with reference to her duties, responsibilities and experience, and to prevailing market conditions, and is subject to annual review by the Remuneration Committee of the Company.

Ms. Ying is the daughter of Mr. Ying Wei, a non-executive Director and controlling shareholder of the Company. As at the date of this announcement, Ms. Ying is indirectly interested in 100,000,000 shares of the Company through Perfect Link Group Limited, the entire issued share capital of which is owned by Ms. Ying, representing approximately 7.47% of the total issued shares of the Company.

Save as disclosed above, Ms. Ying (i) has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other positions in the Company or its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have or is not deemed to have any interests or short positions in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information relating to Ms. Ying that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warm welcome to Ms. Ying for joining the Board.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Mr. Ying Wei (“Mr. Ying”)

Mr. Ying has been appointed as a non-executive Director and a member of each of the Nomination Committee and the Remuneration Committee with effect from 31 October 2025.

The biographical details of Mr. Ying are as follows:

Mr. Ying, aged 59, holds a Master’s Degree in Business Administration from the University of San Francisco and a Bachelor’s Degree in Economics from the Zhejiang Gongshang University (formerly known as Hangzhou Institute of Commerce) in China. He is a non-practising member of the Chinese Institute of Certified Public Accountants.

During 2019 to 2022, he was a director of Sinocelltech Group Limited (a company listed on Shanghai Stock Exchange, stock code: 668520). Mr. Ying is currently a managing partner of CDH Shanghai Dinghui Bai Fu Investment Management Co., Ltd. Mr. Ying is also currently (i) an independent non-executive director of each of Zhongsheng Group Holdings Limited (a company listed on the Stock Exchange, stock code: 881) and Fountain Set (Holdings) Limited (a company listed on the Stock Exchange, stock code: 420); and (ii) a director of Microvast Holdings, Inc. (a company listed on American NASDAQ, stock code: MVST). Mr. Ying had been a non-executive director of the Company during the period from 18 June 2016 to 7 May 2018.

There is no service contract between Mr. Ying and the Company. Mr. Ying has not been appointed for any fixed term but will be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. The remuneration of Mr. Ying will be determined by the Remuneration Committee of the Company subsequently which will be on the basis of his duties and responsibilities within the Company and the prevailing market conditions.

Mr. Ying is the father of Ms. Ying Rensi, an executive Director of the Company. As at the date of this announcement, Mr. Ying is directly interested in 21,075,470 shares of the Company and indirectly interested in 500,000,000 shares of the Company through Ample Colour Limited, the entire issued share capital of which is owned by Mr. Ying, representing approximately 38.91% of the total issued shares of the Company.

Save as disclosed above, Mr. Ying (i) has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other positions in the Company or its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have or is not deemed to have any interests or short positions in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information relating to Mr. Ying that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warm welcome to Mr. Ying for joining the Board.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Wu Hui (“Mr. Wu”)

Mr. Wu has been appointed as an independent non-executive Director, the chairman of Audit Committee and a member of each of the Nomination Committee and the Remuneration Committee with effect from 31 October 2025.

The biographical details of Mr. Wu are as follows:

Mr. Wu, aged 65, obtained a bachelor’s degree from Anhui Finance and Trade Institute (安徽財貿學院, now known as Anhui University of Finance and Economics) in 1986 and a master’s degree in project management from the University of Quebec, Canada, in 2007. Since July 1986, he has been a teaching assistant, lecturer, associate professor, professor, department chairman and deputy head of the teaching supervision team of the Department of Accounting, Hangzhou Institute of Commerce (杭州商學院會計系) (now known as the School of Accounting, Zhejiang Gongshang University (浙江工商大學會計學院)). From June 2013 to July 2019, he served as an independent director of Hangzhou Zhongheng Electric Co., Ltd. (杭州中恒電氣股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 2364). From April 2016 to May 2022, he served as an independent director of Zhejiang Fenglong Electric Co., Ltd. (浙江鋒龍電氣股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 2931). From April 2016 to May 2022, he served as an independent director of Dehua TB New Decoration Material Co., Ltd. (德華兔寶寶裝飾新材股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 2043). From April 2017 to May 2023, he served as an independent director of Chengbang Eco-environment Co., Ltd. (誠邦生態環境股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 603316). Currently, he serves as independent directors of Zhejiang Narada Power Source Co., Ltd. (浙江南都電源動力股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 30068), Hangzhou Greenda Electronic Materials Co., Ltd. (杭州格林達電子材料股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 603931), Loongson Technology Corporation Limited (龍芯中科技術股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 688047) and Zhejiang YuFeng Environment Service Incorporated Company (浙江裕峰環境服務股份有限公司) (a company listed on the National Equities Exchange and Quotations, stock code: 872014).

There is no service contract between Mr. Wu and the Company. Mr. Wu has not been appointed for any fixed term but will be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. The remuneration of Mr. Wu will be determined by the Remuneration Committee of the Company subsequently which will be on the basis of his duties and responsibilities within the Company and the prevailing market conditions.

Save as disclosed above, Mr. Wu (i) has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other positions in the Company or its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have or is not deemed to have any interests or short positions in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Wu has confirmed that he has met the independence criteria set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, there is no other information relating to Mr. Wu that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

Mr. Li Hongyi (“Mr. Li”)

Mr. Li has been appointed as an independent non-executive Director and a member of each of the Audit Committee, the Nomination Committee and the Remuneration Committee with effect from 31 October 2025.

The biographical details of Mr. Li are as follows:

Mr. Li, aged 52, graduated from Sun Yat-sen Medical University (中山醫科大學) in 1996, obtained a master's degree in internal medicine from China Union Medical University (中國協和醫科大學) in 2003, obtained a doctorate degree in internal medicine (cardiovascular diseases) from Capital Medical University (首都醫科大學) in 2021, and served in the department of cardiovascular medicine of Beijing Hospital (北京醫院) since 1996, now serving as chief physician. Mr. Li is currently a professor at the Department of Medicine of Peking University, a doctoral supervisor of Peking Union Medical College (北京協和醫學院) and a director of the Tissue Fluid Circulation Research Centre (組織液循環研究中心). Since 2006, a series of studies have been conducted to validate and establish the third largest systemic fluid circulation network in humans: the acupoint-tissue fluid circulation network. He has presided over one national key research and development programme project, four national natural science funds, two 973 project subjects, one national innovation team of traditional Chinese medicine and one talent support programme project, etc. The relevant achievements have been published in more than 30 high-level national and world magazines, such as iScience, Chinese Medical Journal and Cell Proliferation. He has led the interdisciplinary team to achieve two important results: 1. Discover the anatomical structure of the acupoint-tissue fluid flow network, including a network of tissue fluid flow channels that connect acupoints at the distal end of the extremities of the human body, and are distributed in various locations such as skin, arterial and venous vascular epidural, nerve and fascia; 2. Verify that the periodic and coordinated motion of the heart and lungs is a physiological regulatory mechanism that drives the flow and circulation of tissue fluid in the vascular epidural. Under the action of the cardiopulmonary drive pump, the tissue fluid in the acupoint area at the distal end of the limbs flows along the outer membrane of the vascular tree, forming a tissue fluid circulation network surrounding the heart and the lungs. At present, he has organised a cross-unit, cross-disciplinary, cross-regional excellent research team, under the guidance of the meridian theory, continue to improve and promote the “acupoint-tissue fluid cycle system” theory, research and develop related diagnosis and treatment of new technologies, strive to form a distinctive Chinese-characterised, world-leading original innovative theory of integrated traditional Chinese medicine and Western medicine, and provide systematic theoretical support and clinical practical technology for the “traditional Chinese medicine modernisation” development.

There is no service contract between Mr. Li and the Company. Mr. Li has not been appointed for any fixed term but will be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. The remuneration of Mr. Li will be determined by the Remuneration Committee of the Company subsequently which will be on the basis of his duties and responsibilities within the Company and the prevailing market conditions.

Save as disclosed above, Mr. Li (i) has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other positions in the Company or its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have or is not deemed to have any interests or short positions in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Li has confirmed that he has met the independence criteria set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, there is no other information relating to Mr. Li that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warm welcome to Mr. Wu and Mr. Li for joining the Board.

APPOINTMENT OF THE CHAIRMAN OF THE REMUNERATION COMMITTEE

Ms. Yang Huimin, an independent non-executive director of the Company, has been appointed as the chairman of the Remuneration Committee with effect from 31 October 2025.

The biographical details of Ms. Yang Huimin are as follows:

Ms. Yang Huimin, aged 49, obtained a bachelor's degree in economics from Zhongnan University of Economics (now known as Zhongnan University of Economics and Law) in 1998 and a Master's degree of Management in Nanjing University in 2001. Ms. Yang is a non-practising member of the Chinese Institute of Certified Public Accountants (CPA) and holds the Chartered Financial Analyst qualification (CFA). Ms. Yang has extensive experience in company finance and listed company operations. In 2010 – 2014, she joined COFCO Property (Group) Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 31) and successively became the vice general manager of the financial department, the general manager of the operation department and the vice general manager of the Shenzhen Centre City Company. In 2014 – 2015, Ms. Yang was appointed as the chief financial officer and secretary of the board of directors of COFCO & CM (Shenzhen) Grain Electronic Trading Centre Co., Ltd.. She has been the independent non-executive director of the Company from 18 June 2016 to 7 May 2018. She was re-appointed as independent non-executive director of the Company on 30 December 2024.

RESIGNATION OF EXECUTIVE DIRECTOR AND THE CHAIRMAN OF THE BOARD

Mr. Zhang Fan has resigned as an executive Director, the chairman of the Board and the chairman of the Nomination Committee with effect from 31 October 2025 as he would like to devote more time to his personal business commitments.

Mr. Zhang Fan has confirmed that he had no disagreement with the Board, nor was there any matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its sincere gratitude to Mr. Zhang Fan for his valuable contribution to the Company during his tenure of office.

RESIGNATION OF EXECUTIVE DIRECTOR

Mr. Xing Yong has resigned as an executive Director with effect from 31 October 2025 as he would like to devote more time to his personal business commitments.

Mr. Xing Yong has confirmed that he had no disagreement with the Board, nor was there any matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its sincere gratitude to Mr. Xing Yong for his valuable contribution to the Company during his tenure of office.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

Mr. Wang Jingming has resigned as a non-executive Director with effect from 31 October 2025 as he would like to devote more time to his personal business commitments.

Mr. Wang Jingming has confirmed that he had no disagreement with the Board, nor was there any matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its sincere gratitude to Mr. Wang Jingming for his valuable contribution to the Company during his tenure of office.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Jiang Xuejun, Mr. Du Yanhua and Mr. Lai Liangquan (the “**Resigning INEDs**”) have resigned as an independent non-executive Director as they like to devote more time to their personal business commitments. Upon their respective resignation, each of the Resigning INEDs will also cease to be a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee.

Each of the Resigning INEDs has confirmed that he has no disagreement with the Board and there is nothing to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to his resignation. The Board would like to express its sincere gratitude to each of the Resigning INEDs for their valuable efforts and contributions to the Group during their tenure of office.

By order of the Board
China Health Group Limited
Chung Ho
Chief Executive Officer and Executive Director

Hong Kong, 31 October 2025

As of the date of this announcement, the Board comprises three executive Directors, namely, Mr. Cao Xu (Chairman), Mr. Chung Ho and Ms. Ying Rensi; two non-executive Directors, namely, Mr. Ying Wei and Mr. Huang Lianhai; and three independent non-executive Directors, namely, Mr. Li Hongyi, Mr. Wu Hui and Ms. Yang Huimin.